多発性骨髄腫の生物学的モニタリングにおけるダラツムマブ治療の干渉
Background:
Multiple myeloma is a plasma cell malignancy characterized by monoclonal immunoglobulin production. Daratumumab has improved therapeutic outcomes but can interfere with laboratory assessments.
Methods:
A 73-year-old woman with IgG kappa multiple myeloma achieved remission after initial treatment, then relapsed and received DRD. A monoclonal IgG kappa spike was observed on follow-up SPEP and IFE.
Results:
Daratumumab, due to its IgG1 kappa structure, may mimic disease-related monoclonal proteins, potentially leading to false detection of residual disease and misclassification of complete response as very good partial response.
Conclusions:
Recognizing such interference and ensuring strong clinician-biologist collaboration is essential for accurate response interpretation.
関連する概念動画
Interference and Diffraction
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Interference and Decay
Interference occurs when competing memories hinder the retrieval of particular information. It can be classified into two types: proactive and retroactive interference. Proactive...
Multiple Allele Traits
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
What is Conservation Biology?


